Cancer is the second leading cause of death among women in the United States, with over 270 000 cancer deaths in 2015 ([@bib32]). The use of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor medications ('statins\' or 'HMG Co-A reductase inhibitors\') for cholesterol reduction has been hypothesised to interfere with cancer growth and metastasis through multiple mechanisms ([@bib17]; [@bib22]; [@bib13]; [@bib18]; [@bib28]). Current literature on statin use and cancer survival has been mixed ([@bib12]; [@bib10]; [@bib29]; [@bib8]; [@bib16]; [@bib42]; [@bib43]), although a retrospective nationwide Danish study found a statistically significant 15% reduction in all-cancer mortality among patients who used statins before cancer diagnosis ([@bib31]).

Given the widespread and rapidly growing statin use in the United States ([@bib35]), we aimed to investigate the relationship between statin use and all-cancer survival in the Women\'s Health Initiative (WHI). To our best knowledge, this is the first prospective study to investigate statins and all-cancer survival.

Materials and Methods
=====================

Design, setting, and participants
---------------------------------

The WHI is a large, multi-centre study designed to study major causes of morbidity and mortality in postmenopausal women. The WHI includes a clinical trial (CT) and an observational study (OS) cohort, with details described previously ([@bib21]). Women meeting eligibility criteria (age 50--79, postmenopausal, minimum life expectancy 3 years) were recruited at 40 US clinical centres between 1 September 1993 and 31 December 1998. Primary analyses focused on current statin users among the *N*=23 067 women who experienced an incident cancer during follow-up ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Exposures, confounders, and classification of cases
---------------------------------------------------

WHI implementation details have been previously published ([@bib1]). The medication inventory was repeated at years 1, 3, 6, and 9 for the CT, and year 3 for the OS during the initial study period, which ended on 31 March 2005. The overall follow-up period for the study was through 20 September 2013. Cancers were initially verified at the local clinical centre, and then confirmed by centrally trained physician adjudicators ([@bib11]).

Statistical analysis
--------------------

Multivariable-adjusted Cox regression techniques were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) by modelling two-ordered events: time from enrolment to incident cancer (secondary end point) and time from incident cancer to cancer death (primary end point). Statin use was modelled as a time-dependent categorical variable ([@bib37]), with the following levels: (0) never use, (1) current use (at the time of the latest medication inventory), (2) past use, and (3) out-of-date medication inventory ([@bib19]). The primary analysis compared current (1) *vs* never used statins (0), to investigate the effect of regular statin use.

The Cox proportional hazard analyses were adjusted for potential confounders and included baseline covariates age, race/ethnicity, education, smoking, body mass index, physical activity, family history of cancer, current health-care provider, oral contraception use, prior unopposed oestrogen use, prior oestrogen plus progestin use, solar irradiance (latitude), prior CHD history, prior diabetes history, randomisation into the CaD trial, and age at menarche. Participants who did not die of cancer were censored at death due to other causes, last contact, or out-of-date medication collection.

All analyses were conducted using SAS software, version 9.3 (SAS Institute, Cary, NC, USA) and R software version 2.15 (R Foundation for Statistical, Vienna, Austria).

Results
=======

In our analysis, 146 326 participants contributed 1 805 759 person-years, median (interquartile range, IQR)=14.6 (8.1--16.2) years of follow-up. A cumulative 24 404 women were diagnosed with an incident cancer ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Of this group, 23 067 women had additional follow-up, median (IQR) of 4.8 (1.8--9.4) years, with 7411 all-cause mortalities: 5837 cancer deaths following a diagnosis of incident cancer (78.8%), 613 cardiovascular deaths (8.3%), and 961 other causes (12.9%). After censoring the follow-up of women with out-of-date medication inventories, 3152 cancer deaths were included in the primary analysis of current *vs* never statin users (709 current statin users and 2443 non-users). [Table 1](#tbl1){ref-type="table"}, and [Supplementary Tables 1 and 2](#sup1){ref-type="supplementary-material"} display baseline characteristics.

Current statin use was associated with lower risk of cancer death compared with never-use (HR, 0.78; 95% CI, 0.71--0.86; *P*\<0.001; [Figure 1](#fig1){ref-type="fig"}), and lower risk of all-cause mortality (HR, 0.80; 95% CI, 0.74--0.88). The lower risk of cancer death associated with statin use did not depend on statin potency (*P*-interaction (int)=0.22), category (*P*-int=0.43), type (*P*-int=0.34), or duration (*P*-int=0.33). Other lipid-lowering medications, used alone, were associated with a similar reduction in cancer deaths compared with monotherapy statin use (*P*-int=0.57). Prior statin users were not at lower risk of cancer death compared with never-users (HR, 1.06; 95% CI, 0.85--1.33).

Statin use was associated with a significantly lower risk of multiple, but not all cancer types (*P*-int=0.001; [Figure 2](#fig2){ref-type="fig"}). With the exception of current NSAID use (which attenuated the effect of statins), current statin use was not modified by any other subgroups ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}).

In a secondary analysis on cancer incidence, beginning at enrolment, statin use was not associated with a reduction of incident cancer (HR, 0.96; 95% CI, 0.92--1.001; *P*=0.056).

Discussion
==========

In this prospective cohort study, we found that current statin use in postmenopausal women with cancer was associated with lower risk of cancer death. Use of other lipid-lowering medications was also associated with a lower risk of cancer death; this finding suggests that a reduction in circulating cholesterol levels may mediate increased cancer survival. However, a dose--response relationship was not found, suggesting that results should be interpreted cautiously. Multiple molecular mechanisms have been linked to statins and cancer, including the mevalonate pathway ([@bib17]; [@bib22]; [@bib13]; [@bib5]), G-proteins ([@bib40]; [@bib14]), isoprenoid-mediated suppression ([@bib40]), the RAF-mitogen-activated protein kinase 1 pathway ([@bib41]), and anti-angiogenic properties of statins ([@bib39]).

Comparison with other studies
-----------------------------

Our study results are similar to findings from a retrospective nationwide Danish study, which found a statistically significant 15% reduction in all-cancer mortality among patients who used statins before cancer diagnosis ([@bib31]). Our analysis is additionally strengthened by its prospective format, ethnically heterogeneous population, and covariate data. In addition, other studies of specific cancers in women (including breast and uterine) have suggested the protective effects of statins on cancer mortality and survival ([@bib29]; [@bib8]; [@bib30]). Also, some prospective cohort studies of cardiovascular disease have found associations between lower cholesterol levels and lower risk of death from several cancers ([@bib7]; [@bib25]; [@bib26]).

However, several smaller studies and RCTs have found no significant associations. A meta-analysis of 27 RCTs in the [@bib9] database did not find an association with cancer mortality or incidence; however, the study used the time from randomisation rather than the time from incident cancer. A meta-analysis of 26 RCTs also found no effect of statin use on cancer incidence or survival ([@bib12]). These conflicting results suggest the need for additional prospective studies and larger RCTs, particularly with cancer survival as the primary outcome.

Cancer incidence has been studied more extensively than cancer survival in relation to statin use, but results on the subject have been mixed ([@bib3]; [@bib4]; [@bib6]; [@bib27]; [@bib20]; [@bib24]; [@bib33]; [@bib15]; [@bib34]; [@bib36]). Similarly, biomarker-based studies of statins as candidate breast cancer chemoprevention agents have shown mixed results ([@bib23]; [@bib2]; [@bib38]).

Strengths and limitations
-------------------------

The strengths of this study include its prospective nature, large size and geographic distribution, adjudication of cancer cases, and detailed information on confounders and exposures. Limitations of the study include the fact that medication use was not continuously updated, observational format, and majority Caucasian participants. The study may not be generalisable to populations other than postmenopausal women with similar age at cancer diagnosis. Residual confounding or reverse causation bias may be present.

Healthy user bias due to socioeconomic factors may also present in this analysis; however, this should be reduced as WHI data allow for rich covariate adjustment. In addition, the effect of statin use on cancer survival remained significant even with sensitivity analyses including tumour stage, physical functioning, and mammogram use.

Conclusions
===========

In conclusion, in a prospective cohort of postmenopausal women, current use of statins and other cholesterol-lowering medications was associated with increased all-cancer survival, as well as increased survival of multiple cancer types. These findings, along with the previous Danish cohort study, suggest that statin use and/or lower cholesterol levels may have a protective effect on cancer death. Further research is needed in an RCT format to better control for healthy user bias and to study cancer as a primary outcome.
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![**Number of cancer deaths (annualised %) and multivariable-adjusted HR (95% CI) for statin use (current *vs* never).**Annualised percentages by exposure group (time dependent) were computed by dividing the total number of cancer deaths, by the corresponding cumulative person-time since cancer diagnosis, for each exposure group. Cox regression models were adjusted for age at baseline, race/ethnicity, education, smoking, body mass index (BMI), physical activity, family history of cancer, current health-care provider, oral contraception use, prior unopposed oestrogen use, prior oestrogen plus progestin use, solar irradiance (latitude), prior CHD history, prior diabetes history, randomisation into the CaD trial, age at menarche, and stratified by age group, study groups (randomisation arms of the HT trials, DM trial, and OS enrolment) and enrolment in WHI extensions (I/II). \*Annualised percentage. \*\*Significance test of the main effect or test of heterogeneity between non-referent exposure groups. †Test of heterogeneity between atorvastatin, simvastatin, lovastatin, and pravastatin. ‡Analysis of statin duration included only CT participants; at the time of cancer diagnosis, among current statin users (*n*=2218), 893 (40.3%) used statins \<3 years, 539 (24.3%) 3 to \<5 years, 593 (26.7%) 5 to \<10 years, and 193 (8.7%) 10+ years. Test of heterogeneity based on a 1 degree-of-freedom test for trend. \^Test of heterogeneity between statin use and other use.](bjc2016149f1){#fig1}

![**Number of cancer deaths (annualised %) and multivariable-adjusted HR (95% CI) for statin use (current *vs* never) by cause of cancer death.**Summary statistics are from a Cox regression model, using cause-specific baseline hazard functions, with the covariate adjustments described above. \*Corresponds to a significance test of the main effect, or an 11-df test of heterogeneity for cause of cancer death. To avoid double counting, test of heterogeneity is between the main causes of death listed and does not include subtypes (i.e., cancer of the pancreas or other digestive organs, non-Hodgkins lymphoma, and leukaemia). \^Only participants without a baseline hysterectomy were used to compute the number of cases and annualised rates. There was one endometrial cancer case among the group of no statin use that reported having had a hysterectomy.](bjc2016149f2){#fig2}

###### Participants\' characteristics in the Women\'s Health Initiative Clinical Trial and Observational Study by statin use (current *vs* never)[a](#t1-fn2){ref-type="fn"} at time of cancer diagnosis (*N*=17 285[b](#t1-fn3){ref-type="fn"})

                                                                **Current statin use (*****N*****=4025)**   **Never used statins (*****N*****=13 260)**                          
  ------------------------------------------------------------ ------------------------------------------- --------------------------------------------- ---------- ------------ -------------------
  Age at screening (years)                                                                                                                                                             \<0.001
   50--59                                                                         1123                                         27.9                         3973        30.0               
   60--69                                                                         2089                                         51.9                         6228        47.0               
   70--79                                                                          813                                         20.2                         3059        23.1               
  Age at incident cancer                                                                                                                                                               \<0.001
   \<70                                                                           1338                                         33.2                         6706        50.6               
   70 to \<80                                                                     2030                                         50.4                         5295        39.9               
   ⩾80                                                                             657                                         16.3                         1259        9.5                
  Tumour stage                                                                                                                                                                          0.001
   *In situ*                                                                       613                                         15.9                         1732        13.8               
   Local                                                                          1924                                         49.8                         6203        49.4               
   Regional                                                                        702                                         18.2                         2552        20.3               
   Distant                                                                         623                                         16.1                         2079        16.5               
  Race/ethnicity                                                                                                                                                                        0.15
   White                                                                          3517                                         87.4                        11 701       88.2               
   Black                                                                           261                                          6.5                         832         6.3                
   Hispanic                                                                        86                                           2.1                         310         2.3                
   American Indian                                                                 16                                           0.4                          38         0.3                
   Asian/Pacific Islander                                                          92                                           2.3                         234         1.8                
   Unknown                                                                         53                                           1.3                         145         1.1                
  Education                                                                                                                                                                            \<0.001
   High school/GED or less                                                         899                                         22.5                         2617        19.9               
   School after high school                                                       1534                                         38.3                         4812        36.5               
   College degree or higher                                                       1570                                         39.2                         5746        43.6               
  BMI, baseline (kg m^−2^)                                                                                                                                                             \<0.001
   \<25                                                                           1065                                         26.7                         4745        36.1               
   25 to \<30                                                                     1474                                         37.0                         4468        33.9               
   30 to \<35                                                                      882                                         22.1                         2427        18.4               
   ⩾35                                                                             568                                         14.2                         1522        11.6               
  Smoking status                                                                                                                                                                        0.75
   Never                                                                          1829                                         46.0                         6115        46.7               
   Past                                                                           1817                                         45.7                         5904        45.1               
   Current                                                                         326                                          8.2                         1074        8.2                
  Vitamin D intake (IU)                                                                                                                                                                 0.97
   \<200                                                                          1418                                         36.2                         4690        36.1               
   200 to \<400                                                                    737                                         18.8                         2483        19.1               
   400 to \<600                                                                    981                                         25.0                         3229        24.9               
   ⩾600                                                                            784                                         20.0                         2577        19.9               
  Alcohol intake                                                                                                                                                                       \<0.001
   Non/past drinker                                                               1121                                         28.1                         3252        24.7               
   \<1 drink per week                                                             1376                                         34.5                         4367        33.2               
   1--\<7 drinks per week                                                          986                                         24.7                         3656        27.8               
   ⩾7 drinks per week                                                              511                                         12.8                         1890        14.4               
  Physical activity (MET---min)                                                                                                                                                         0.03
   \<100                                                                           824                                         21.7                         2683        21.6               
   100 to \<500                                                                   1127                                         29.7                         3420        27.5               
   500 to \<1200                                                                  1081                                         28.4                         3620        29.1               
   ⩾1200                                                                           768                                         20.2                         2709        21.8               
  Has current health-care provider                                                3845                                         96.1                        12 401       94.3           \<0.001
  Mammogram within last 2 years                                                   3465                                         88.1                        10 822       84.1           \<0.001
  Hysterectomy at randomisation                                                   1526                                         37.9                         4702        35.5            0.005
  Unopposed oestrogen use status                                                                                                                                                        0.64
   Never used                                                                     2668                                         66.4                         8752        66.1               
   Past user                                                                       509                                         12.7                         1752        13.2               
   Current user                                                                    843                                         21.0                         2746        20.7               
  Oestrogen+progesterone use status                                                                                                                                                    \<0.001
   Never used                                                                     2934                                         72.9                         9166        69.2               
   Past user                                                                       340                                          8.5                         1123        8.5                
   Current user                                                                    748                                         18.6                         2964        22.4               
  Age at menarche                                                                                                                                                                       0.31
   \<12                                                                            894                                         22.3                         2900        22.0               
   12--13                                                                         2262                                         56.4                         7336        55.6               
   ⩾14                                                                             856                                         21.3                         2970        22.5               
  Oral contraceptive use ever                                                     1672                                         41.5                         5451        41.1            0.63
  CHD before cancer diagnosis                                                      680                                         17.0                         756         5.7            \<0.001
  Diabetes before cancer diagnosis                                                 725                                         18.0                         865         6.5            \<0.001
  Family history of cancer                                                        2639                                         68.4                         8888        69.8            0.12
  Aspirin use                                                                     1136                                         28.2                         2573        19.4           \<0.001
  NSAIDs                                                                          1684                                         41.8                         4478        33.8           \<0.001
  DM trial                                                                                                                                                                              0.03
   Comparison                                                                     1011                                         62.8                         2985        59.6               
   Intervention                                                                    600                                         37.2                         2020        40.4               
  CEE+MPA trial                                                                                                                                                                         0.007
   Comparison                                                                      283                                         52.7                         819         46.1               
   Intervention                                                                    254                                         47.3                         957         53.9               
  CEE trial                                                                                                                                                                             0.04
   Comparison                                                                      179                                         56.5                         423         49.6               
   Intervention                                                                    138                                         43.5                         430         50.4               
  CaD trial                                                                                                                                                                             0.15
   Comparison                                                                      638                                         53.1                         1856        50.7               
   Intervention                                                                    563                                         46.9                         1803        49.3               
  Clinical trial participant                                                      2218                                         55.1                         6830        51.5           \<0.001
                                                                                **Mean**                                    **(s.d.)**                    **Mean**   **(s.d.)**   ***P*****-value**
  Age (years)                                                                     63.6                                         (6.5)                        63.7       (7.0)            0.37
  Fruit and vegetable consumption[d](#t1-fn5){ref-type="fn"}                       4.0                                         (4.0)                        4.1        (2.1)            0.004
  Red meat consumption[d](#t1-fn5){ref-type="fn"}                                  0.7                                         (0.5)                        0.7        (0.6)            0.27
  General health (0 worst--100 best)                                              73.6                                        (17.2)                        75.9       (16.7)          \<0.001

Abbrviations: BMI=body mass index; CaD=calcium + Vitamin D; CEE=conjugated equine estrogen; CHD=coronary heart disease; DM=dietary Modification; GED=general education development; MET=metabolic equivalent; MPA=medroxyprogesterone acetate; NSAID=nonsteroidal anti-inflammatory drugs.

Statin (current *vs* never) were the exposure groups of interest for the primary analysis.

At the time of incident cancer, 23 067 participants were at risk for death and included in the primary analyses. Of these, 4025 participants were currently taking statins; 13 260 participants never used statins; 397 participants had reported using statins at baseline or follow-up, but were not currently taking statins; and 5385 participants had medication inventories that were out of date, so their follow-up was censored. Exposure groups were modelled as a time-dependent exposure, so a participants\' group status may change during follow-up (e.g., participants with an out-of-date inventory were allowed to re-enter the model when a current medications inventory was collected).

On the basis of *χ*^2^-test of association for categorical variables and *t*-test for continuous variables.
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